肠康方通过约氏乳杆菌-吲哚-3-乳酸-AhR/IL-22轴恢复IBS-D肠脑稳态
该研究探讨中药复方肠康方(CKF)治疗腹泻型肠易激综合征(IBS-D)的机制。采用束缚应激、夹尾和番泻叶灌胃诱导IBS-D模型,通过16S rRNA测序和代谢组学分析发现CKF重塑肠道菌群,富集约氏乳杆菌并增强色氨酸代谢;粪菌移植证实菌群介导疗效,约氏乳杆菌或其代谢物吲哚-3-乳酸(ILA)通过激活AhR/IL-22通路重现肠脑获益。
要点
- CKF可改善IBS-D模型腹泻、内脏高敏感及焦虑抑郁样行为
- CKF疗效依赖肠道菌群重塑,关键菌为约氏乳杆菌
- 约氏乳杆菌-ILA-AhR-IL-22轴增强肠屏障与血脑屏障完整性
核心结论
- CKF通过约氏乳杆菌-ILA-AhR-IL-22轴恢复肠脑稳态,是治疗IBS-D的菌群调节疗法。
研究设计与样本
- 采用束缚应激、夹尾和番泻叶灌胃诱导IBS-D模型,评估肠道功能、炎症和行为。
- 通过16S rRNA测序和代谢组学分析菌群与代谢物,粪菌移植验证菌群因果作用。
- 体内验证关键菌与代谢物,并分析肠屏障、系统性炎症、海马血脑屏障、神经炎症和突触可塑性。
主要发现
- CKF缓解腹泻、内脏高敏感、炎症、屏障功能障碍及焦虑抑郁样行为。
- CKF重塑肠道菌群,富集约氏乳杆菌并增强色氨酸代谢;粪菌移植证实菌群介导疗效。
- 补充约氏乳杆菌或其代谢物ILA通过激活AhR/IL-22通路重现肠脑获益。
- CKF诱导的约氏乳杆菌富集激活ILA-AhR-IL-22通路,增强肠屏障和血脑屏障完整性,减轻系统性及神经炎症,恢复海马突触可塑性。
临床怎么用
- CKF可作为IBS-D的潜在治疗选择,其机制与调节肠道菌群和肠脑轴相关。
- 约氏乳杆菌和ILA可能成为IBS及其共病的潜在治疗靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Gut dysbiosis contributes to irritable bowel syndrome (IBS) by disrupting intestinal barrier functions and promoting inflammation. Chang‑kang‑fang (CKF), a Chinese herbal formula proven effective for diarrhea‑predominant IBS (IBS‑D) in a phase III trial, is thought to modulate the gut microbiota, yet the underlying mechanism remains unclear. PURPOSE: To elucidate how CKF ameliorates IBS‑D by modulating the gut microbiota. METHODS: IBS‑D was induced by restraint stress, tail pinch, and senna gavage. Intestinal function, inflammation, and behavior were evaluated. Gut microbiota and metabolites were profiled via 16S rRNA sequencing and metabolomics. FMT confirmed the causal involvement of the microbiota. The key microbe and metabolite were validated in vivo. Mechanistic analyses evaluated intestinal barrier integrity, systemic inflammation, hippocampal blood‑brain barrier (BBB) function, neuroinflammation, and synaptic plasticity. RESULTS: CKF alleviated diarrhea, visceral hypersensitivity, inflammation, barrier dysfunction, and anxiety‑ and depression‑like behaviors. These benefits were associated with gut microbiota remodeling, featuring enrichment of Lactobacillus johnsonii and enhanced tryptophan metabolism. FMT confirmed that this microbial remodeling mediates the therapeutic effects of CKF. Supplementation with L. johnsonii or its metabolite indole‑3‑lactic acid (ILA) largely recapitulated these gut-brain benefits via AhR/IL‑22 activation. Mechanistically, CKF‑induced L. johnsonii enrichment activated the ILA-AhR-IL‑22 pathway, which enhanced intestinal and BBB integrity, thereby attenuating systemic and neuroinflammation, and restoring hippocampal synaptic plasticity. CONCLUSION: This study positions CKF as a microbiota‑modulating therapy for IBS‑D that restores gut‑brain homeostasis via the L. johnsonii-ILA-AhR-IL‑22 axis, highlighting L. johnsonii and ILA as potential therapeutics for IBS and its comorbidities.
引用
- Yang F, Tian D, Zhang Y, et al. Traditional Chinese medicine formulation Chang-Kang-Fang restores gut-brain homeostasis in IBS-D via the Lactobacillus johnsonii-indole-3-lactic acid-aryl hydrocarbon receptor/interleukin-22 axis. Phytomedicine. 2026. PMID: 42727456. doi:10.1016/j.phymed.2026.158786
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。